Swedish Orphan Biovitrum EBITDA 2019-2025 | BIOVF

Swedish Orphan Biovitrum EBITDA for the quarter ending June 30, 2025 was $0.206B, a 46.62% increase year-over-year.

  • Swedish Orphan Biovitrum 2024 EBITDA was 0.88B, a 28.49% increase from 2023.
  • Swedish Orphan Biovitrum 2023 EBITDA was 0.685B, a 10.95% increase from 2022.
  • Swedish Orphan Biovitrum 2022 EBITDA was 0.617B, a 7.72% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Swedish Orphan Biovitrum EBITDA 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum 2024 EBITDA was 0.88B, a 28.49% increase from 2023.
  • Swedish Orphan Biovitrum 2023 EBITDA was 0.685B, a 10.95% increase from 2022.
  • Swedish Orphan Biovitrum 2022 EBITDA was 0.617B, a 7.72% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$245.4B
Amgen (AMGN)$157.5B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100B
Bristol Myers Squibb (BMY)$98.1B
CSL (CSLLY)$85.5B
GSK (GSK)$79.6B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$59.9B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26.9B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19.9B
Incyte (INCY)$16.6B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
Moderna (MRNA)$10.9B
QIAGEN (QGEN)$10.8B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.1B
Roivant Sciences (ROIV)$8B
Anbio Biotechnology (NNNN)$7.4B